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Abstract
Background: The presence of a high neutrophil-to-lymphocyte ratio (NLR) has been associated with increased
mortality in several malignancies. Here, we quantify the effect of NLR on survival in patients with breast cancer,
and examine the effect of clinicopathologic factors on its prognostic value.
Methods: A systematic search of electronic databases was conducted to identify publications exploring the association
of blood NLR (measured pre treatment) and overall survival (OS) and disease-free survival (DFS) among patients with
breast cancer. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) or a P value were pooled
in a meta-analysis. Pooled HRs were computed and weighted using generic inverse variance. Meta-regression
was performed to evaluate the influence of clinicopathologic factors such as age, disease stage, tumor grade,
nodal involvement, receptor status, and NLR cutoff on the HR for OS and DFS. All statistical tests were two-sided.
Results: Fifteen studies comprising a total of 8563 patients were included. The studies used different cutoff values to
classify high NLR (range 1.9–5.0). The median cutoff value for high NLR used in these studies was 3.0 amongst 13
studies reporting a HR for OS, and 2.5 in 10 studies reporting DFS outcomes. NLR greater than the cutoff value was
associated with worse OS (HR 2.56, 95% CI = 1.96–3.35; P < 0.001) and DFS (HR 1.74, 95% CI = 1.47–2.07; P < 0.001). This
association was similar in studies including only early-stage disease and those comprising patients with both early-stage
and metastatic disease. Estrogen receptor (ER) and HER-2 appeared to modify the effect of NLR on DFS, because NLR had
greater prognostic value for DFS in ER-negative and HER2-negative breast cancer. No subgroup showed an influence on
the association between NLR and OS.
Conclusions: High NLR is associated with an adverse OS and DFS in patients with breast cancer with a greater effect on
disease-specific outcome in ER and HER2-negative disease. NLR is an easily accessible prognostic marker, and its addition
to established risk prediction models warrants further investigation.
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Background
The short-term and long-term prognosis of breast cancer
depends on patient and tumor factors such as age, disease
stage, and biological factors such as grade and receptor
status. However, the behavior of breast cancer is unpre-
dictable, with markedly different clinical outcomes seen
even amongst patients with similar classical prognostic
factors [1].
Inflammatory cells and mediators in the tumor micro-
environment are thought to play an important role in
cancer progression, and may account for some of this
variability [2]. The presence of an elevated peripheral
neutrophil-to-lymphocyte (NLR) ratio, an indicator of
systemic inflammation, has been recognized as a poor prog-
nostic factor in various cancers [3]. In a previous meta-
analysis of 100 studies of patients with unselected solid
tumors, increased NLR was associated with decreased
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overall survival (OS) (hazard ratio (HR) 1.81; 95% con-
fidence interval (CI) = 1.67–1.97; P < 0.001) [4]. This
effect was observed in all disease sites, subgroups, and
stages. However, this study was not specific to breast
cancer, and did not examine the impact of prognostic
factors such as estrogen receptor (ER) or progesterone
receptor (PR) status, HER2 status, disease stage, or
menopausal status.
The aim of this study was to quantify the effect of
peripheral blood NLR on OS and disease-free survival
(DFS) in adult women with invasive breast cancer. We
also examined the effect of clinicopathologic factors on
the prognostic value of NLR.
Methods
Data sources and searches
This analysis was reported in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [5]. The search
strategy developed by Templeton et al. [4] was used with
the addition of “breast neoplasms” and synonymous breast
cancer-specific terms. An electronic search of the follow-
ing databases was performed: Medline (host: OVID),
Medline in Process, Medline Epub Ahead of Print (host:
OVID), EMBASE (host: OVID), and Cochrane Database
of Systematic Reviews. All databases were searched from
January 2013 to April 2016, supplementing the initial
systematic review that searched databases until different
time points in 2013. Citation lists of retrieved articles were
screened manually to ensure sensitivity of the search strat-
egy. The full search strategy is described in Table 3 in
Appendix 1.
Study selection
In order to reduce clinical heterogeneity, the following
eligibility criteria were utilized: studies of adult women
with breast cancer reporting on the prognostic impact of
the peripheral blood NLR, where NLR was treated as a
categorical variable; NLR collected prior to all treatment
(surgery and/or systemic therapy); reporting of a multi-
variable HR for OS, and/or DFS or progression-free sur-
vival (PFS), and corresponding 95% CI and/or P value;
available as a full-text publication; clinical trials, cohort
studies, or case–control studies; and English-language
publication. Case reports, conference proceedings, and
letters to editors were excluded. Corresponding authors
were contacted to clarify missing or ambiguous data.
When multiple publications or data analyses were available
from the same dataset and if clarification on potentially
duplicate data could not be obtained, the study reporting
the larger number of patients was retained and other stud-
ies were excluded. Studies only presenting data in graphic
form without reporting a numerical value for HR were
excluded. All titles identified by the search were evaluated,
and all potentially relevant publications were retrieved in
full. Two reviewers (JE and DD) independently reviewed
full articles for eligibility based on inclusion criteria and
data extraction, and disagreements were resolved by con-
sensus. Three relevant articles identified in the previous
systematic review were also included [4].
Data extraction
The following details were extracted from included studies
using predesigned data abstraction forms: name of first
author, year of publication, journal, number of patients
included in analysis, median age, disease stage (nonme-
tastatic, metastatic, mixed (nonmetastatic and meta-
static)), collection of data (prospective, retrospective),
cutoff value used to define high NLR, number of patients
with each breast cancer subtype, number of premeno-
pausal and postmenopausal patients, and HRs and associ-
ated 95% CIs for OS, PFS, or DFS. Where more than one
multivariable model was reported, HRs were extracted
from models including the most participants.
Risk of bias assessment
Validity of included studies was assessed by two inde-
pendent reviewers (J-LE and DD) using the Quality in
Prognostic Studies (QUIPS) tool as described previously
[6]. The QUIPS tool comprises 30 questions categorized
into six domains (study participation, study attrition,
prognostic factor measurement, outcome measurement,
study confounding, and statistical analysis and reporting).
Studies were rated according to each domain as being at
low, moderate, or high risk of bias, based on the likelihood
that they might alter the relationship between the prog-
nostic factor and outcome.
Statistical analyses
Extracted data were pooled using RevMan 5.3 analysis
software (Cochrane Collaboration, Copenhagen, Denmark).
A meta-analysis was conducted for all included studies for
each of the endpoints of interest if appropriate when clin-
ical heterogeneity was minimal. The primary outcome of
interest was OS, and intermediate endpoints such as PFS
and/or DFS were secondary outcomes. Estimates for HRs
were pooled and weighted by generic inverse variance, and
were computed by fixed-effects or random-effects model-
ing. Heterogeneity was assessed using Cochran Q and I2
statistics. If significant heterogeneity was present (I2 > 50%
or Cochran Q < 0.1), a random-effects model was used. Pre-
defined subgroup analyses were conducted for disease stage
(early, metastatic, mixed) using methods described by
Deeks et al. [7] Meta-regression was performed to evaluate
the effects of NLR cutoff, proportion of ER-positive pa-
tients, proportion of HER2-positive patients, proportion of
triple-negative patients, median age, proportion of premen-
opausal patients, and proportion of patients with metastatic
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disease on the HR for OS and DFS. Meta-regression
comprised a univariable linear regression weighted by
individual study inverse variance and was performed
using SPSS version 24 (IBM Corp, Armonk, NY, USA).
A post-hoc meta-regression analysis testing the associ-
ation between median duration of follow-up and the prog-
nostic value of NLR was also performed. Multivariable
meta-regression was not performed due to the small num-
ber of eligible studies leading to an undesirable risk of
over-fitting. Publication bias was assessed by inspecting
funnel plots visually. All statistical tests were two-sided,
and statistical significance was defined as P < 0.05.
Results
Fifteen studies comprising a total of 8563 patients were
included (Fig. 1). Characteristics of included studies
are described in Table 1, and further details are in-
cluded in Table 4 in Appendix 2. All studies collected
data retrospectively, and all were published in 2012 or
later. Ten studies included only patients with early-
stage breast cancer, while five included both early and
metastatic disease.
Overall survival
Thirteen studies comprising a total of 8015 patients
reported adjusted HRs for OS. The median cutoff
value for high NLR was 3.0 (range 2.0–5.0). Median
follow-up was reported in 11 studies, and ranged from
1.8 to 7.2 years (mean 4.69 years) (Table 4 in Appendix 2).
Overall, a NLR greater than the cutoff value was associ-
ated with worse OS (HR 2.56, 95% CI = 1.96–3.35; P <
0.001; see Fig. 2). There was statistically significant hetero-
geneity (Cochran Q = 0.009, I2 = 55%). This seems to be
largely influenced by one study which showed a large
effect size [8]. However, the association between NLR
and OS was maintained in a sensitivity analysis omitting
Fig. 1 Flow chart of study selection process. HR hazard ratio, NLR neutrophil-to-lymphocyte
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this study (HR 2.42, 95% CI = 1.89–3.09; P < 0.001;
Cochran Q = 0.03, I2 = 48%), although statistically signifi-
cant heterogeneity remained.
Exploratory analysis identified breast cancer stage as
an important source of heterogeneity. Subgroup analysis
showed that the association between NLR and OS was
maintained in studies including only early-stage disease,
as well as those comprised of patients with both early
and metastatic disease (HR 2.98 vs 2.30 respectively; P
for subgroup differences = 0.36). There was no statistical
heterogeneity when the study driving heterogeneity in
the main analysis [8] was omitted from the early stage
subgroup (Cochran Q = 0.28, I2 = 20%). Additionally, the
effect of NLR on OS was retained (HR 2.56, 95% CI =
1.82–3.60; P < 0.001). Statistical heterogeneity remained
among studies with mixed early and metastatic disease
(Cochran Q = 0.01, I2 = 69%).
Adjustment for age differences between arms was ex-
amined in individual studies. In one study, patients were
significantly older in the arm with low NLR, and it was
unclear whether the multivariable model was adjusted
for age [9]. In two other studies, the median age in each
arm was not reported, and age did not seem to be in-
cluded in the multivariable model [10, 11]. In a sensitivity
analysis excluding these three studies, high NLR remained
a significant predictor for shorter OS (HR 2.55, 95% CI =
2.59–8.26; P < 0.001). Table 2 presents the results of the
meta-regression analysis. We did not identify any classical
clinicopathologic factors that were effect modifiers for in-
fluence of NLR on OS. Additionally, the median duration
of follow-up did not affect the association between high
NLR and OS.
There was evidence of publication bias, with fewer
smaller studies reporting lower magnitude associations
between NLR and OS (Fig. 3).
Disease-free survival
Nine studies comprising 4864 patients reported HRs for
DFS. All studies included only patients with nonmeta-
static disease. The median cutoff value for high NLR
was 2.5 (range 1.9–4.0). Median length of follow-up was
reported in eight studies, ranging from 1.8 to 7.2 years
(mean 4.5 years) (Table 4 in Appendix 2). Overall, a
NLR greater than the cutoff value was associated with
worse DFS (HR 1.74, 95% CI = 1.47–2.07; P < 0.001; see
Fig. 2). There was no evidence of statistically significant
heterogeneity (Cochran Q = 0.14, I2 = 35%).
Adjustment for age differences between arms was
examined in individual studies. Two studies had signifi-
cant age differences between arms and no clear model
adjustment for age, including one study where patients
were significantly older in the arm with low NLR [9]
and one study where the same group was significantly
younger [12]. Another study did not report the median
age in each arm and did not adjust for age in the multivar-
iable model [10]. In a sensitivity analysis excluding these
three studies, high NLR remained a significant predictor
for shorter DFS (HR 1.69, 95% CI = 1.40–2.03; P < 0.001).
All studies reported the number of patients with HER2-
positive disease, while seven of nine studies included data
on ER status (Table 4 in Appendix 2). Meta-regression
analysis is presented in Table 2. Results showed that
ER and HER2 positivity were negative effect modifiers
of the association between NLR and DFS, indicating
that the NLR has a greater prognostic value in breast
cancers that are ER-negative and/or HER2-negative.
The proportion of patients with triple-negative or
metastatic disease, median age, disease stage, histologic
tumor grade, presence of nodal involvement, premeno-
pausal status, median duration of follow-up, and NLR
cutoff value did not affect the association between high
NLR and DFS. There was evidence of publication bias,
with fewer smaller studies reporting lower magnitude
associations between NLR and DFS (Fig. 3).
Table 1 Characteristics of included studies







Azab et al. [23]a 2012 316 Mixed 3.3
Azab et al. [13]a 2013 437 Mixed 3.3
Bozkurt et al. [24] 2015 85 Early 2.0
Dirican et al. [25] 2015 1527 Mixed 4.0
Forget et al. [10] 2014 720 Early 3.3
Jia et al. [14] 2015 1570 Early 2.0
Koh et al. [8] 2014 157 Early 2.3
Koh et al. [15] 2015 1435 Mixed 5.0
Nakano et al. [9] 2015 167 Early 2.5
Noh et al. [26]a 2013 442 Early 2.5
Pistelli et al. [27] 2015 90 Early 3.0
Rimando et al. [28] 2016 461 Mixed 3.8
Yao et al. [11] 2014 608 Early 2.6
Disease-free survival
Asano et al. [12] 2016 61 Early 3.0
Bozkurt et al. [24] 2015 85 Early 2.0
Dirican et al. [25] 2015 1527 Mixed 4.0
Forget et al. [10] 2014 720 Early 3.3
Hong et al. [29] 2015 487 Early 1.9
Jia et al. [14] 2015 1570 Early 2.0
Koh et al. [8] 2014 157 Early 2.3
Nakano et al. [9] 2015 167 Early 2.5
Pistelli et al. [27] 2015 90 Early 3.0
NLR neutrophil-to-lymphocyte
aIncluded in previous meta-analysis [4]
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Risk of bias assessment
The risk of bias in individual studies is summarized in
Figure 4 in Appendix 3. Overall, risk of bias was low,
particularly in the domains of study attrition, prognostic
factor measurement, outcome measurement, and statistical
analysis and reporting. There was a low–moderate risk of
bias for the study participation domain due to lack of
completeness in description of the baseline study sample
in three studies [8, 13, 14]. Risk of bias was moderate with
regards to study confounding, because four studies failed
to adequately detail covariates included in adjusted models
[8, 10, 12, 15].
Discussion
High NLR is associated with poor survival in patients
diagnosed with several types of cancer [4]. Here we
performed a breast cancer-specific meta-analysis, in-
cluding 15 studies comprising 8563 patients, and
found a significant prognostic effect for NLR on both
OS and DFS. While there was evidence of publication
bias, potentially indicating bias towards publication of
positive studies, the overall risk of bias was low, as
assessed with the QUIPS tool.
The magnitude of effect on DFS was highest in ER-
negative and HER2-negative subtypes. However, this
finding does not rule out an effect in ER-positive or
HER2-positive subgroups. Rather, the finding indicates
a greater magnitude of effect in ER-negative and/or
HER2-negative breast cancers. It is possible that the
smaller magnitude of effect seen in ER-positive and/or
HER2-positive disease relates to the relatively short
duration of follow-up of included studies; recurrences
occur later in follow-up with ER-positive disease com-
pared with ER-negative disease. However, in a post-hoc
meta-regression analysis, median follow-up did not signifi-
cantly alter the association of NLR with either DFS or OS.
Unfortunately, a stratified meta-regression based on ER
status was not possible. Some uncertainty therefore re-
mains about the effect of duration of follow-up on sub-
groups defined by receptor expression.
Despite a greater magnitude of association between
NLR and DFS in certain subgroups, patient and disease
characteristics did not significantly alter the magnitude
of effect of NLR on OS. The negative prognostic effect
of NLR on OS was consistent in all clinicopathologic
groups and was not influenced by the duration of


















Heterogeneity: P = 0.009; I² = 55%































0.01 0.1 1 10 100












Heterogeneity: P = 0.14; I² = 35%























0.01 0.1 1 10 100
Favours High NLR Favours Low NLR
Fig. 2 Forest plots showing HRs for OS (a) and DFS (b) for neutrophil-to-lymphocyte ratio (NLR) greater than or less than the cutoff value. HRs for
each study represented by squares: size of the square represents the weight of the study in the meta-analysis, and the horizontal line crossing the
square represents the 95% confidence interval (CI). All statistical tests were two-sided
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for this is that a proportion of breast cancer patients die
of causes other than breast cancer, especially cardiovas-
cular disease [16, 17]. Increased NLR has been associ-
ated with higher coronary heart disease mortality [18].
The competing risks of cardiovascular and breast cancer
deaths may have led to difficulty in exploring the influ-
ence of breast cancer-specific characteristics on OS.
While the association between increased NLR and poor
outcomes is not fully understood, it has been proposed that
high NLR may be indicative of inflammation. In particular,
neutrophils have been shown to inhibit the immune system
and promote tumor growth by suppressing the activity of
lymphocytes and T-cell response [19, 20]. Increased
lymphocytic tumor infiltration has also been associated
with improved DFS in ER-negative/HER2-negative breast
cancer [21]. In our study, we found a greater magnitude of
effect on DFS in patients with ER-negative and/or HER2-
negative disease. However, while this indicates the potential
importance of lymphocyte activity, the association between
increased tumor-infiltrating lymphocytes and peripheral
blood lymphocytes remains unclear. Furthermore, the
greater magnitude of association in patients with ER-
negative and/or HER2-negative breast cancers was not
seen with triple-negative disease. This observation may be
due to the relatively small number of studies reporting
outcomes in patients with triple-negative breast cancer;
Table 2 Meta-regression for the association of clinicopathologic factors and the hazard ratio for disease-free and overall survival
Variable Studies included in analysis Standardized β coefficient P value
Overall survival
Median age [8, 9, 11, 13–15, 26–28] 0.098 0.80
ER positive [9–11, 13, 15, 23–27] 0.084 0.81
HER2 positive [8–11, 14, 15, 23–27] –0.40 0.22
Triple negative [8, 14, 24, 27] 0.05 0.93
Grade 1 or 2 [8, 10, 14, 15, 23–25] 0.02 0.95
Grade 3 [8, 10, 14, 15, 23–25] –0.02 0.95
Stage 0–I [9, 13, 23, 25, 27, 28] 0.68 0.14
Stage II [9, 13, 23, 25, 27, 28] –0.30 0.56
Stage III [9, 13, 25, 27, 28] –0.73 0.16
Metastatic disease [8–11, 13–15, 24–28] –0.29 0.35
Premenopausal [24, 25] 0.04 0.95
Nodal involvement [8–11, 13–15, 23–27] –0.04 0.90
NLR cutoff value [8, 10, 13–15, 23, 24] –0.29 0.33
Median follow-up [8–11, 13, 14, 23, 25–28] –0.16 0.64
Disease-free survival
Median age [8, 9, 14, 27, 29] 0.06 0.93
ER positive [9, 10, 12, 24, 25, 27, 29] –0.77 0.04*
HER2 positive [8–10, 12, 14, 24, 25, 27, 29] –0.79 0.01*
Triple negative [8, 12, 14, 24, 27, 29] 0.63 0.18
Grade 1 or 2 [8–10, 12, 14, 24, 25, 27, 29] –0.46 0.21
Grade 3 [8–10, 12, 14, 24, 25, 27, 29] 0.46 0.21
Stage 0–I [9, 25, 27, 29] 0.46 0.54
Stage II [9, 25, 27, 29] 0.53 0.36
Stage III [9, 25, 27, 29] –0.50 0.39
Metastatic disease [25] –0.74 0.49
Premenopausal [9, 12, 24, 25, 27] 0.43 0.40
Nodal involvement [8–10, 12, 14, 24, 25, 27, 29] 0.25 0.52
NLR cutoff value [8–10, 12, 14, 24, 25, 27, 29] –0.15 0.70
Median follow-up [8–10, 12, 14, 25, 27, 29] –0.19 0.66
ER estrogen receptor, NLR neutrophil-to-lymphocyte
*Statistically significant at P < 0.05
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the majority of studies identified patients based on inde-
pendent subgroups based on ER and HER2 status.
While there are several clinicopathologic factors
associated with increased risk of recurrence and/or
mortality in patients with breast cancer, the NLR is an
inexpensive, readily available prognostic marker, and
may allow refinement of risk estimates within disease
stages and subgroups. Future studies using NLR in
combination with other prognostic markers could po-
tentially identify lower risk patients in whom treat-
ment de-escalation may be appropriate. Furthermore,
whether NLR is predictive of response to treatment or
provides additional information in cases where risk
stratification models exist, such as the 21-gene assay
in node-negative ER-positive/HER2-negative disease,
is unknown. However, previous research showed no
association between NLR and the 21-gene assay recur-
rence score, indicating that the poor outcomes in
patients with high NLR cannot be explained by the
proliferation of ER signaling [22]. Further studies
examining whether NLR may help refine established
prognostic scores are therefore warranted.
Conclusion
High NLR is associated with an adverse OS and DFS
in patients with breast cancer, and its prognostic
value is consistent among different clinicopathologic
factors such as disease stage and subtype. NLR is an
easily accessible prognostic marker, and its addition
to established risk prediction models warrants fur-
ther investigation.
Fig. 3 Funnel plots of HR for OS (a) and DFS (b) for high NLR ratio (horizontal axis) and the standard error (SE) for the HR (vertical axis). Each
study is represented by one circle. Vertical line represents the pooled effect estimate
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Appendix 1
Table 3 Search strategya
Number Searches Results Type
1 exp Breast Neoplasms/ 241,242 Advanced
2 (breast? adj6 cancer*).mp,kw. 203,097 Advanced
3 (breast? adj6 neoplas*).mp,kw. 241,382 Advanced
4 (breast? adj6 carcin*).mp,kw. 62,218 Advanced
5 (breast? adj6 tumo?r*).mp,kw. 46,556 Advanced
6 (breast? adj6 adenocarcin*).mp,kw. 4642 Advanced
7 (breast? adj6 adeno-carcin*).mp,kw. 10 Advanced
8 (breast? adj6 sarcoma*).mp,kw. 1271 Advanced
9 (breast? adj6 dcis).mp,kw. 1258 Advanced
10 (breast? adj6 ductal).mp,kw. 16,064 Advanced
11 (breast? adj6 infiltrating).mp,kw. 1418 Advanced
12 (breast? adj6 intraductal).mp,kw. 2294 Advanced
13 (breast? adj6 lobular).mp,kw. 4044 Advanced
14 (breast? adj6 medullary).mp,kw. 383 Advanced
15 (breast? adj6 comedo*).mp,kw. 75 Advanced
16 (breast? adj6 metast*).mp,kw. 26,054 Advanced
17 (breast? adj2 malignan*).mp,kw. 4962 Advanced
18 (breast? adj6 onco*).mp,kw. 3338 Advanced
19 (mammar* adj6 cancer*).mp,kw. 5493 Advanced
20 (mammar* adj6 neoplas*).mp,kw. 21,985 Advanced
21 (mammar* adj6 carcin*).mp,kw. 11,584 Advanced
22 (mammar* adj6 tumo?r*).mp,kw. 18,026 Advanced
23 (mammar* adj6 adenocarcin*).mp,kw. 2958 Advanced
24 (mammar* adj6 adeno-carcin*).mp,kw. 3 Advanced
25 (mammar* adj6 sarcoma*).mp,kw. 384 Advanced
26 (mammar* adj6 ductal).mp,kw. 937 Advanced
27 (mammar* adj6 intraductal).mp,kw. 117 Advanced
28 (mammar* adj6 infiltrating).mp,kw. 201 Advanced
29 (mammar* adj6 lobular).mp,kw. 151 Advanced
30 (mammar* adj6 medullary).mp,kw. 19 Advanced
31 (mammar* adj6 comedo*).mp,kw. 6 Advanced
32 (mammar* adj6 metast*).mp,kw. 2554 Advanced
33 (mammar* adj6 malignan*).mp,kw. 1506 Advanced
34 (mammar* adj6 dcis).mp,kw. 61 Advanced
35 (ductal adj6 situ).mp,kw. 6301 Advanced
36 (ductal adj6 carcino*).mp,kw. 25,790 Advanced
37 (paget?? adj6 breast?).mp,kw. 367 Advanced
38 (paget?? adj6 nipple?).mp,kw. 363 Advanced
39 phyllodes.mp,kw. 1876 Advanced
40 phylloides.mp,kw. 206 Advanced
41 cystosarcoma*.mp,kw. 603 Advanced
42 DCIS.mp,kw. 3401 Advanced
43 or/1-40 318,397 Advanced
44 exp Ovarian Neoplasms/ 71,707 Advanced
45 (ovar* adj6 cancer*).mp,kw. 44,037 Advanced
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Table 3 Search strategya (Continued)
46 (ovar* adj6 neoplas*).mp,kw. 71,929 Advanced
47 (ovar* adj6 tumo?r*).mp,kw. 24,113 Advanced
48 (ovar* adj6 malignan*).mp,kw. 7601 Advanced
49 (ovar* adj6 metasta*).mp,kw. 5781 Advanced
50 (ovar* adj6 carcin*).mp,kw. 18,742 Advanced
51 (ovar* adj6 adenocarcin*).mp,kw. 2966 Advanced
52 (ovar* adj6 adeno-carcin*).mp,kw. 12 Advanced
53 (ovar* adj6 choriocarcin*).mp,kw. 217 Advanced
54 (granulosa adj6 cancer*).mp,kw. 54 Advanced
55 (granulosa adj6 tumo?r*).mp,kw. 2699 Advanced
56 (granulosa adj6 neoplas*).mp,kw. 173 Advanced
57 (granulosa adj6 malignan*).mp,kw. 142 Advanced
58 (granulosa adj6 metasta*).mp,kw. 111 Advanced
59 (granulosa adj6 carcin*).mp,kw. 118 Advanced
60 (granulosa adj6 adenocarcin*).mp,kw. 45 Advanced
61 (granulosa adj6 adeno-carcin*).mp,kw. 0 Advanced
62 OGCTs.mp,kw. 28 Advanced
63 HBOC.mp,kw. 650 Advanced
64 Luteoma*.mp,kw. 203 Advanced
65 Sertoli-Leydig*.mp,kw. 1039 Advanced
66 Thecoma*.mp,kw. 1013 Advanced
67 (theca* adj6 tumo?r*).mp,kw. 493 Advanced
68 (ovar* adj6 dysgerminoma?).mp,kw. 467 Advanced
69 androblastoma*.mp,kw. 321 Advanced
70 arrhenoblastoma*.mp,kw. 349 Advanced
71 arrheno-blastoma*.mp,kw. 1 Advanced
72 Meig*.mp,kw. 2152 Advanced
73 or/44-72 93,590 Advanced
74 exp Endometrial Neoplasms/ 17,416 Advanced
75 (endometr* adj6 neoplas*).mp,kw. 17,866 Advanced
76 (endometr* adj6 cancer*).mp,kw. 15,307 Advanced
77 (endometr* adj6 tumo?r*).mp,kw. 5128 Advanced
78 (endometr* adj6 carcino*).mp,kw. 12,730 Advanced
79 (endometr* adj6 adenocarcin*).mp,kw. 5361 Advanced
80 (endometr* adj6 adeno-carcin*).mp,kw. 9 Advanced
81 (endometr* adj6 sarcoma*).mp,kw. 1230 Advanced
82 (endometr* adj6 malignan*).mp,kw. 2300 Advanced
83 (endometr* adj6 metast*).mp,kw. 1337 Advanced
84 (endometr* adj6 onco*).mp,kw. 370 Advanced
85 (endometr* adj6 choriocarcin*).mp,kw. 88 Advanced
86 or/74-85 31,774 Advanced
87 Uterine Cervical Neoplasms/ 65,130 Advanced
88 (cervi* adj6 cancer*).mp,kw. 41,277 Advanced
89 (cervi* adj6 neoplas*).mp,kw. 69,153 Advanced
90 (cervi* adj6 tumo?r*).mp,kw. 7715 Advanced
91 (cervi* adj6 malignan*).mp,kw. 3006 Advanced
92 (cervi* adj6 metast*).mp,kw. 6612 Advanced
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Table 3 Search strategya (Continued)
93 (cervi* adj6 onco*).mp,kw. 1280 Advanced
94 (cervi* adj6 carcin*).mp,kw. 24,588 Advanced
95 (cervi* adj6 adenocarcin*).mp,kw. 2945 Advanced
96 (cervi* adj6 adeno-carcin*).mp,kw. 9 Advanced
97 (cervi* adj6 squamous*).mp,kw. 7833 Advanced
98 (cervi* adj6 adenosquamous*).mp,kw. 211 Advanced
99 (cervi* adj6 adeno-squamous*).mp,kw. 2 Advanced
100 (cervi* adj6 sarcoma*).mp,kw. 661 Advanced
101 (cervi* adj6 small cell*).mp,kw. 364 Advanced
102 (cervi* adj6 large cell*).mp,kw. 78 Advanced
103 (cervi* adj6 neuroendocrine*).mp,kw. 195 Advanced
104 (cervi* adj6 neuro-endocrine*).mp,kw. 2 Advanced
105 (cervi* adj6 choriocarcin*).mp,kw. 112 Advanced
106 SCCC.mp,kw. 46 Advanced
107 or/87-106 90,890 Advanced
108 73 or 86 or 107 199,155 Advanced
109 exp Lymphocytes/ 461,529 Advanced
110 lymphocyte?.mp,kw. 554,948 Advanced
111 (lymphoid adj2 cell?).mp,kw. 22,666 Advanced
112 (killer adj4 cell?).mp,kw. 51,337 Advanced
113 (nk adj2 cell?).mp,kw. 31,413 Advanced
114 (lak adj2 cell?).mp,kw. 2650 Advanced
115 b-lymphocyte?.mp,kw. 93,264 Advanced
116 t-lymphocyte?.mp,kw. 290,882 Advanced
117 b-lymphoid.mp,kw. 2219 Advanced
118 t-lymphoid.mp,kw. 1196 Advanced
119 (plasm adj2 cell?).mp,kw. 31 Advanced
120 plasmacyte?.mp,kw. 341 Advanced
121 (immune adj3 cell?).mp,kw. 58,743 Advanced
122 (immunocompetent adj2 cell?).mp,kw. 3494 Advanced
123 immnunocyte?.mp,kw. 0 Advanced
124 immnuno-cyte?.mp,kw. 0 Advanced
125 lymph cell?.mp,kw. 184 Advanced
126 null cell?.mp,kw. 3404 Advanced
127 immunological* competent cell?.mp,kw. 153 Advanced
128 immunoreactive cell?.mp,kw. 6231 Advanced
129 immuno-reactive cell?.mp,kw. 18 Advanced
130 prolymphocyte?.mp. 218 Advanced
131 pro-lymphocyte?.mp. 3 Advanced
132 or/109-131 648,538 Advanced
133 Neutrophils/ 77,202 Advanced
134 neutrophil*.mp,kw. 135,327 Advanced
135 (cell? adj2 le).mp,kw. 868 Advanced
136 (leukocyte? adj3 polymorphonuclear).mp,kw. 14,471 Advanced
137 pmn granulocyte?.mp,kw. 52 Advanced
138 pmn leukocyte?.mp,kw. 400 Advanced
139 (poly morphou* adj2 granulocyte?).mp,kw. 0 Advanced
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Table 3 Search strategya (Continued)
140 (polynuclear adj3 leukocyte?).mp,kw. 71 Advanced
141 or/133-140 139,999 Advanced
142 (neutrophil? adj6 lymphocyte?).mp,kw. 8790 Advanced
143 NLR.mp,kw. 1729 Advanced
144 132 and 141 26,722 Advanced
145 or/142-144 27,810 Advanced
146 exp Cohort Studies/ 1,522,637 Advanced
147 exp Prognosis/ 1,240,142 Advanced
148 exp Morbidity/ 425,952 Advanced
149 exp Mortality/ 309,548 Advanced
150 exp survival analysis/ 214,369 Advanced
151 exp models, statistical/ 311,009 Advanced
152 prognos*.mp,kw. 603,945 Advanced
153 predict*.mp,kw. 1,026,266 Advanced
154 course*.mp,kw. 467,535 Advanced
155 diagnosed.mp,kw. 361,373 Advanced
156 cohort*.mp,kw. 388,862 Advanced
157 death?.mp,kw. 646,834 Advanced
158 or/146-157 4,572,550 Advanced
159 108 and 145 and 158 64 Advanced
160 43 and 145 and 158 122 Advanced
161 159 or 160 184 Advanced
162 limit 161 to yr = “2013-Current” 85 Advanced
aOvid MEDLINE®, 1946–April week 2 2016
























Asano et al. [12] 2016 61 Early 3.0 n/a 0 0 100 72 28 36 3.1
Azab et al. [23] 2012 316 Mixed 3.3 n/a 83 17 n/a 70 30 n/a 3.8
Azab et al. [13] 2013 437 Mixed 3.3 64 76 n/a n/a n/a n/a n/a 5
Bozkurt et al. [24] 2015 85 Early 2.0 n/a 0 0 100 31 69 69 n/a
Dirican et al. [25] 2015 1527 Mixed 4.0 n/a 68 17 n/a 80 20 44 2.5
Forget et al. [10] 2014 720 Early 3.3 n/a 84 9 n/a 61 39 n/a 5.8
Hong et al. [29] 2015 487 Early 1.9 55 67 21 19 73 27 42 4.6
Jia et al. [14] 2015 1570 Early 2.0 47 n/a 22 14 62 38 n/a 6.6
Koh et al. [8] 2014 157 Early 2.3 44 n/a 0 0 80 20 n/a 1.8
Koh et al. [15] 2015 1435 Mixed 5.0 52 55 36 100 56 44 n/a n/a
Nakano et al. [9] 2015 167 Early 2.5 58 78 18 n/a 80 20 25 7.2a
Noh et al. [26] 2013 442 Early 2.5 50 71 29 18 71 29 n/a 5.9
Pistelli et al. [27] 2015 90 Early 3.0 53 0 0 100 10 90 40 4.5
Rimando et al. [28] 2016 461 Mixed 3.8 58 74 n/a n/a 51 49 n/a 5.1
Yao et al. [11] 2014 608 Early 2.6 53 66 25 16 n/a n/a 48 3.5
ER estrogen receptor, n/a not available, NLR neutrophil-to-lymphocyte
aMean follow-up
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